Boehringer Ingelheim registers Phase 3 safety rollover trial of obrixtamig in advanced cancer
The study, first posted on ClinicalTrials.gov on November 10, 2026, plans to enroll 68 participants and begin in March 2027. It plans to find out how well participants who received obrixtamig in a previous study tolerate the drug.
Primary source
ClinicalTrials.gov registry record, November 10, 2026
A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
Read the source: A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation